Welcome to our dedicated page for ORGANON & news (Ticker: OGN), a resource for investors and traders seeking the latest updates and insights on ORGANON & stock.
Organon & Co. reports developments as a global healthcare company with portfolios in Women's Health and General Medicines, including biosimilars. Company news commonly covers operating results, product and regulatory updates, and clinical data for medicines such as VTAMA cream for atopic dermatitis and plaque psoriasis, biosimilar approvals including POHERDY, and established women's health brands and devices such as Nexplanon, Follistim, and Jada.
Updates also address capital-structure disclosures, governance matters, shareholder voting topics, and material agreements, alongside the company's commercial activity across more than 140 markets.
Organon, a global healthcare company focusing on women's health, announced the pricing of $1.0 billion Senior Notes Offering, consisting of $500 million of 6.750% senior secured notes and $500 million of 7.875% senior unsecured notes. The proceeds will be used to repay borrowings and cover related expenses. The offering is expected to close on May 17, 2024.
Organon, a global healthcare company focusing on women's health, plans to offer $1.0 billion in senior notes, consisting of $500 million in secured notes and $500 million in unsecured notes. The proceeds will be used to repay borrowings and cover related expenses. The offering is not registered under the U.S. Securities Act and is targeted at qualified institutional buyers and non-U.S. persons.
Organon (NYSE: OGN) reported impressive first-quarter 2024 results, with revenue reaching $1,622 million, up 5% on an as-reported basis and 7% at constant currency. Diluted earnings per share were $0.78, with non-GAAP adjusted earnings per share at $1.22. The company reaffirmed its full-year 2024 financial guidance. Women's Health revenue grew by 11%, Biosimilars revenue by 46%, and Established Brands revenue remained flat. Overall, Organon had a solid start to the year, focusing on growth while maintaining its commitment to improving women's health.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.